Xtant Medical to Issue Fourth Quarter and Full Year 2017 Financial Results Monday, April 2

Xtant Medical to Issue

Fourth Quarter and Full Year 2017 Financial Results Monday, April 2

BELGRADE, Mont., March 27, 2018 (ACCESSWIRE) -- Xtant Medical

Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced

that it will release its financial results for the fourth quarter and full year ended December 31, 2017, after the close of the

financial markets on Monday, April 2, 2018.

An accompanying conference call will be conducted by Carl O'Connell,

Chief Executive Officer and President, and Laura Kendall, Interim Chief Financial Officer, to review the results. The call will

be held at 9:00 AM ET, on Tuesday, April 3, 2018. Please refer to the information below for conference call dial-in information

and webcast registration.

Conference Date: Tuesday, April 3, 2018 9:00 AM ET

Conference dial-in: 877-269-7756

International dial-in: 201-689-7817

Conference Call Name: Xtant Medical Holdings, Inc. Fourth Quarter

and Full Year 2017 Results Conference Call

Webcast Registration: Click Here

Following the live call, a replay will be available on the Company's

website, www.xtantmedical.com, under "Investor Info".

Xtant Medical develops, manufactures and markets regenerative

medicine products and medical devices for domestic and international markets. Xtant Medical products serve the specialized needs

of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation

for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing

following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies,

Xtant Medical can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further

information, please visit www.xtantmedical.com.

Important Cautions Regarding Forward-looking Statements

This press release contains certain disclosures that may be

deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to

significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon

or refer to future events or conditions, or that include words such as "continue," "efforts," "expects,"

"anticipates," "intends," "plans," "believes," "estimates," "projects,"

"forecasts," "strategy," "will," "goal," "target," "prospects," "potential,"

"optimistic," "confident," "likely," "probable" or similar expressions or the negative

thereof.Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by

their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors,

including, among others: the ability to comply with covenants in the Company's senior credit facility; the ability to increase

revenue; the ability to achieve expected results; the ability to remain competitive; government regulations; the ability to innovate

and develop new products; the ability to obtain donor cadavers for products; the ability to engage and retain qualified technical

personnel and members of the Company's management team; the availability of Company facilities; government and third-party

coverage and reimbursement for Company products; the ability to obtain regulatory approvals; the ability to successfully integrate

recent and future business combinations or acquisitions; the ability to use net operating loss carry-forwards to offset future

taxable income; the ability to service Company debt; product liability claims and other litigation to which we may be subjected;

product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property

and proprietary rights; infringement and ownership of intellectual property; the ability to remain accredited with the American

Association of Tissue Banks; influence by Company management; the ability to pay dividends; and the ability to issue preferred

stock; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports

on Form 10-Q under the heading "Risk Factors." You should carefully consider the trends, risks and uncertainties described

in this document, the Form 10-K and other reports filed with or furnished to the SEC before making any investment decision with

respect to our securities. If any of these trends, risks or uncertainties actually occurs or continues, our business, financial

condition or operating results could be materially adversely affected, the trading prices of our securities could decline, and

you could lose all or part of your investment. The Company undertakes no obligation to release publicly any revisions to any forward-looking

statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except

as required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in

their entirety by this cautionary statement.